Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IRITACE: TACE with Irinotecan + Mitomycin C vs Doxorubicin in Hepatocellular Carcinoma
DRKS00017416Phase 2Terminated
- Sponsor
- Universitätsmedizin Frankfurt
- Start
- Mar 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in hepatocellular carcinoma (HCC) comparing DEB-TACE irinotecan + mitomycin C with DEB-TACE doxorubicin (2 arms). Started Mar 2020; status: terminated.
02
Drugs
irinotecanmitomycin cdoxorubicin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on DRKS00017416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00017416.